Roche bans rivals from comparing copycat drugs to Herceptin

Pharmaceutical group Roche said it secured an injunction from an Indian court banning generic drug makers Biocon and Mylan from comparing their copycat versions of Roche's Herceptin breast cancer treatment to the original. Mylan and Biocon, which co-developed breast cancer drugs CANMab and Hertraz they say are biosimilars of Herceptin, are no longer allowed to refer to Herceptin or its manufacturing process, safety, efficacy and sales when communicating about their drugs, the New Delhi High Court ruled on Wednesday.